IFN-gamma in Candida albicans infections
- PMID: 19273178
- DOI: 10.2741/3356
IFN-gamma in Candida albicans infections
Abstract
The dimorphic fungus Candida albicans is the most frequent etiologic agent that causes opportunistic infections called candidiasis, a disease whose systemic manifestation could prove fatal and whose incidence is increasing as a result of an expanding immunocompromised population. Here we review the role of interferon-gamma (IFN-gamma) in the host protection against invasive candidiasis. This cytokine plays an essential role in both the innate and adaptive arms of the immune response to candidiasis. We focus on recent progress on host-pathogen interactions at the molecular level, leading to the production of IFN-gamma by host cells. IFN-gamma is produced by CD4 Th1, CD8, gamma delta T, and natural killer (NK) cells, essentially in response to both IL-12 and/or IL-18, and plays an important role in the regulation of the immune system as well as in the control of the infectious process. IFN-gamma is required for optimal activation of phagocytes, collaborates in the generation of protective antibody response, and favours the development of a Th1 protective response.
Similar articles
-
Role of IFN-gamma in immune responses to Candida albicans infections.Front Biosci (Landmark Ed). 2014 Jun 1;19(8):1279-90. doi: 10.2741/4281. Front Biosci (Landmark Ed). 2014. PMID: 24896350 Review.
-
NK cells regulate CD8+ T cell effector function in response to an intracellular pathogen.J Immunol. 2004 Jan 1;172(1):130-7. doi: 10.4049/jimmunol.172.1.130. J Immunol. 2004. PMID: 14688318
-
[TH1 response in the experimental infection with Trypanosoma cruzi].Medicina (B Aires). 1999;59 Suppl 2:84-90. Medicina (B Aires). 1999. PMID: 10668248 Spanish.
-
Interleukin-12 but not interferon-gamma production correlates with induction of T helper type-1 phenotype in murine candidiasis.Eur J Immunol. 1994 Apr;24(4):909-15. doi: 10.1002/eji.1830240419. Eur J Immunol. 1994. PMID: 7908634
-
Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts).Clin Ter. 2006 Jul-Aug;157(4):377-86. Clin Ter. 2006. Retraction in: Clin Ter. 2008 May-Jun;159(3):207. PMID: 17051976 Retracted. Review.
Cited by
-
Promising immunotherapeutic targets for treating candidiasis.Front Cell Infect Microbiol. 2024 Feb 9;14:1339501. doi: 10.3389/fcimb.2024.1339501. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 38404288 Free PMC article. Review.
-
Secretion of IFN-γ by Transgenic Mammary Epithelial Cells in vitro Reduced Mastitis Infection Risk in Goats.Front Vet Sci. 2022 Jun 24;9:898635. doi: 10.3389/fvets.2022.898635. eCollection 2022. Front Vet Sci. 2022. PMID: 35812858 Free PMC article.
-
Impairment of host defense against disseminated candidiasis in mice overexpressing GATA-3.Infect Immun. 2010 May;78(5):2302-11. doi: 10.1128/IAI.01398-09. Epub 2010 Mar 15. Infect Immun. 2010. PMID: 20231412 Free PMC article.
-
The Role of B-Cells and Antibodies against Candida Vaccine Antigens in Invasive Candidiasis.Vaccines (Basel). 2021 Oct 10;9(10):1159. doi: 10.3390/vaccines9101159. Vaccines (Basel). 2021. PMID: 34696267 Free PMC article. Review.
-
Candida pneumonia in the ICU: myth or reality?Intensive Care Med. 2009 Sep;35(9):1500-2. doi: 10.1007/s00134-009-1563-8. Epub 2009 Jun 27. Intensive Care Med. 2009. PMID: 19562321 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous